121 related articles for article (PubMed ID: 15467913)
21. Human blood platelet gC1qR/p33.
Peerschke EI; Ghebrehiwet B
Immunol Rev; 2001 Apr; 180():56-64. PubMed ID: 11414364
[TBL] [Abstract][Full Text] [Related]
22. Blood platelets activate the classical pathway of human complement.
Peerschke EI; Yin W; Grigg SE; Ghebrehiwet B
J Thromb Haemost; 2006 Sep; 4(9):2035-42. PubMed ID: 16961611
[TBL] [Abstract][Full Text] [Related]
23. Factor XII and kininogen asymmetric assembly with gC1qR/C1QBP/P32 is governed by allostery.
Kaira BG; Slater A; McCrae KR; Dreveny I; Sumya U; Mutch NJ; Searle M; Emsley J
Blood; 2020 Oct; 136(14):1685-1697. PubMed ID: 32559765
[TBL] [Abstract][Full Text] [Related]
24. Isolation and characterization of the kininogen-binding protein p33 from endothelial cells. Identity with the gC1q receptor.
Herwald H; Dedio J; Kellner R; Loos M; Müller-Esterl W
J Biol Chem; 1996 May; 271(22):13040-7. PubMed ID: 8662673
[TBL] [Abstract][Full Text] [Related]
25. gC1qR/p33 blockade reduces Staphylococcus aureus colonization of target tissues in an animal model of infective endocarditis.
Peerschke EI; Bayer AS; Ghebrehiwet B; Xiong YQ
Infect Immun; 2006 Aug; 74(8):4418-23. PubMed ID: 16861627
[TBL] [Abstract][Full Text] [Related]
26. The binding protein for globular heads of complement C1q, gC1qR. Functional expression and characterization as a novel vitronectin binding factor.
Lim BL; Reid KB; Ghebrehiwet B; Peerschke EI; Leigh LA; Preissner KT
J Biol Chem; 1996 Oct; 271(43):26739-44. PubMed ID: 8900153
[TBL] [Abstract][Full Text] [Related]
27. gC1qR Antibody Can Modulate Endothelial Cell Permeability in Angioedema.
Fandaros M; Joseph K; Kaplan AP; Rubenstein DA; Ghebrehiwet B; Yin W
Inflammation; 2022 Feb; 45(1):116-128. PubMed ID: 34494203
[TBL] [Abstract][Full Text] [Related]
28. Prokaryotic expression, purification, and reconstitution of biological activities (Antiprotease, antitumor, and heparin-binding) for tissue factor pathway inhibitor-2.
Rao CN; Reddy P; Reeder DJ; Liu Y; Stack SM; Kisiel W; Woodley DT
Biochem Biophys Res Commun; 2000 Oct; 276(3):1286-94. PubMed ID: 11027624
[TBL] [Abstract][Full Text] [Related]
29. Expression of gC1q-R/p33 and its major ligands in human atherosclerotic lesions.
Peerschke EI; Minta JO; Zhou SZ; Bini A; Gotlieb A; Colman RW; Ghebrehiwet B
Mol Immunol; 2004 Jul; 41(8):759-66. PubMed ID: 15234555
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor.
Petersen LC; Sprecher CA; Foster DC; Blumberg H; Hamamoto T; Kisiel W
Biochemistry; 1996 Jan; 35(1):266-72. PubMed ID: 8555184
[TBL] [Abstract][Full Text] [Related]
31. Interaction of factor XII and high molecular weight kininogen with cytokeratin 1 and gC1qR of vascular endothelial cells and with aggregated Abeta protein of Alzheimer's disease.
Joseph K; Shibayama Y; Nakazawa Y; Peerschke EI; Ghebrehiwet B; Kaplan AP
Immunopharmacology; 1999 Sep; 43(2-3):203-10. PubMed ID: 10596854
[TBL] [Abstract][Full Text] [Related]
32. Classical pathway complement activation on human endothelial cells.
Yin W; Ghebrehiwet B; Weksler B; Peerschke EI
Mol Immunol; 2007 Mar; 44(9):2228-34. PubMed ID: 17173972
[TBL] [Abstract][Full Text] [Related]
33. Assessment of the role of heparan sulfate in high molecular weight kininogen binding to human umbilical vein endothelial cells.
Fernando LP; Fernando AN; Joseph K; Kaplan AP
J Thromb Haemost; 2003 Nov; 1(11):2444-9. PubMed ID: 14629481
[TBL] [Abstract][Full Text] [Related]
34. The C1q and gC1qR axis as a novel checkpoint inhibitor in cancer.
Ghebrehiwet B; Zaniewski M; Fernandez A; DiGiovanni M; Reyes TN; Ji P; Savitt AG; Williams JL; Seeliger MA; Peerschke EIB
Front Immunol; 2024; 15():1351656. PubMed ID: 38711524
[TBL] [Abstract][Full Text] [Related]
35. Identification of a novel 33-kDa C1q-binding site on human blood platelets.
Peerschke EI; Reid KB; Ghebrehiwet B
J Immunol; 1994 Jun; 152(12):5896-901. PubMed ID: 8207215
[TBL] [Abstract][Full Text] [Related]
36. Complement component C1q initiates extrinsic coagulation via the receptor for the globular head of C1q in adventitial fibroblasts and vascular smooth muscle cells.
Freda CT; Yin W; Ghebrehiwet B; Rubenstein DA
Immun Inflamm Dis; 2023 Jan; 11(1):e769. PubMed ID: 36705413
[TBL] [Abstract][Full Text] [Related]
37. Kininogen binding protein p33/gC1qR is localized in the vesicular fraction of endothelial cells.
Dedio J; Müller-Esterl W
FEBS Lett; 1996 Dec; 399(3):255-8. PubMed ID: 8985157
[TBL] [Abstract][Full Text] [Related]
38. gC1q-R/p33, a member of a new class of multifunctional and multicompartmental cellular proteins, is involved in inflammation and infection.
Ghebrehiwet B; Lim BL; Kumar R; Feng X; Peerschke EI
Immunol Rev; 2001 Apr; 180():65-77. PubMed ID: 11414365
[TBL] [Abstract][Full Text] [Related]
39. Subcellular targeting of multiligand-binding protein gC1qR.
Dedio J; Renné T; Weisser M; Müller-Esterl W
Immunopharmacology; 1999 Dec; 45(1-3):1-5. PubMed ID: 10614982
[TBL] [Abstract][Full Text] [Related]
40. Plasmin proteolysis of endothelial cell and vessel wall associated tissue factor pathway inhibitor.
Stalboerger PG; Panetta CJ; Simari RD; Caplice NM
Thromb Haemost; 2001 Sep; 86(3):923-8. PubMed ID: 11583328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
